1·The findings also support prior research linking rofecoxib (Vioxx) with adverse cardiovascular effects.
该研究也支持以前关于罗非考昔（Vioxx）与心血管副作用相关的结论。
2·Rofecoxib users had the highest event rates, while naproxen users had the lowest, even lower than non users.
罗非考昔使用者的心血管事件发生率最高，而萘普生的发生率最低，甚至比不应用药物的人还要低。
3·The MI rate ratio with rofecoxib use was 1.59 in patients with a prior MI and 1.23 in those without a previous MI.
使用罗非昔布并且有心梗病史的患者心梗发生率为1.59%，而没有心梗病史的患者心梗发生率只有1.23%。
4·Rofecoxib improved response rate and several quality-of-life items, including pain-related items and global quality of life.
罗非考昔可提高患者治疗反应率和数个生活质量项目，包括疼痛相关项目和总的生活质量。
5·Rofecoxib significantly increased the incidence of diarrhoea and decreased constipation, fatigue, fever, weight loss, and pain, and analgesic consumption.
罗非考昔能显著增加腹泻和降低便秘、疲劳、发热、体重减轻、疼痛和止痛剂消耗发生率。
6·Further analysis showed that of the various NSAIDs evaluated, only rofecoxib and ibuprofen increased the risk of cardiovascular events across patient subgroups.
对不同的非甾体抗炎药的评估后进一步分析显示，在整个患者亚群中仅仅罗非考昔和布洛芬增加了心血管事件发生的风险。
7·Conclusion: Rofecoxib administrated for a long term has no harm influence on the collagenic metabolism of the rats' knee joints cartilage in experimental osteoarthrosis.
结论：长期服用罗非昔布对大鼠骨关节病关节软骨的胶原代谢无明显影响。